Brief: Relmada Therapeutics Acquires Potential Therapy For Tourette Syndrome From Asarina Pharma AB
06/02/2025 11:55
Feb 6 (Reuters) - Relmada Therapeutics Inc RLMD.O :
* RELMADA THERAPEUTICS ACQUIRES POTENTIAL THERAPY FOR
TOURETTE
SYNDROME FROM ASARINA PHARMA AB
* RELMADA THERAPEUTICS: PURCHASES SEPRANOLONE, FOR
TREATMENT OF
TOURETTE SYNDROME AND OTHER COMPULSION-RELATED CONDITIONS FROM
ASARINA PHARMA AB
Source text: ID:n0001213900-25-010711
Further company coverage: RLMD.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Relmada Therapeutics
See all newsRelmada Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
Brief: Relmada Therapeutics Q2 EPS USD -0.11
Relmada Therapeutics Inc expected to post a loss of 20 cents a share - Earnings Preview
Brief: Relmada Therapeutics Appoints Uro-Oncology Leader Bipin Dalmia As Chief Business Officer
Brief: Relmada Therapeutics - Increases Authorized Common Stock To 200 Million Shares From 150 Million